Dopamine Agonists
Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study
... and dopamine agonists were effective in reducing syndrome ’ s symptoms by 46% (P = ...the dopamine agonists significantly improved sleep quality (P = ...with dopamine agonists, ...
11
Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
... Dopaminergic treatment seems to be a particular risk fac- tor for psychoses in PD. Several reports have described an induction of psychosis by most of the common dopamine agonists (DA) [19-26]. ...
6
The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study
... Dopamine agonists (DAs) are the first-choice drugs for treatment of the early stage of Parkinson’ s disease (PD) in patients younger than 70 years of age ...postsynaptic dopamine receptors, con- ...
6
Augmentative dopaminergic interventions for treatment-resistant bipolar depression: a focus on dopamine agonists and stimulants
... adjunctive dopamine agonists and stimu- lants cannot be, at present, included among well-estab- lished, evidence-based strategies for treatment of bipolar depressed patients who fail to respond to ...
14
A case of ectopic ACTH syndrome treated with intermittent administration of dopamine agonists
... of dopamine agonists in Cushing’s disease were performed with bromocriptine; however, the effect was not strong and was maintained over the longer term in only a small subset of ...the dopamine type ...
6
Die Therapie der Parkinsonerkrankung mit Dopaminagonisten The treatment of Parkinson's disease with dopamine agonists
... Die Studien zu den nicht-ergoten Dopaminagonisten zeigten wie auch die ergoten eine gute Wirkung auf Dys- kinesien, als Monotherapie zu Beginn der Erkrankung eingesetzt kann der Beginn d[r] ...
11
The development of a knowledge base for basic active structures: an example case of dopamine agonists
... A different approach to extract structural characteris- tics from active compounds can be seen in CASE [11] and MultiCASE [12] developed by Klopmann. These methods use linear fragments and search through com- binations ...
13
Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease
... In the article “Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease,” Dr. Klepitskaya et al. reported sustained improvement in symptoms of restless legs syndrome (RLS) over 2 years ...
5
Restless legs syndrome: a new entity of neuropathic pain? Treatment with prolonged release oxycodone/naloxone combination
... that dopamine agonists exert a direct action on the excitability of the spinal cord, whereas α 2 δ ligands and opioids act indirectly attenuating peripheral inputs, and this provides a rationale for ...
5
Problems Associated with Non Ergot Dopamine Agonist Maintenance Therapy in Patients with Advanced Parkinson’s Disease
... a dopamine agonist can delay the appearance of motor complications [13], but dopamine agonists become ineffective for motor disorders after about 10 years [14] ...the dopamine agonist dose may ...
7
EFFECTS OF DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS ON BACLOFEN-INDUCED ANTINOCICEPTION IN FORM ALIN TEST
... of dopamine neurons in the ventral tegmental area28 and reduces the turnover of brain ...potentiates dopamine-induced behaviours in ...Since dopamine may be the neurotransmitter involved in baclofen ...
8
Central Pain in Parkinson’s Disease: A Case Report
... Pain in Parkinson’s disease is common, with an estimated prevalence up to 85% of those with the disease. Central pain in Parkinson’s disease is poorly understood and the role of pharmacological treatment, including the ...
9
tial therapy, especially in cases where tremor is predominant, but there is evidence that anticho- linergic agents are better than levodopa for tremor (class II).
... Abstract—In 1993, the last AAN Practice Parameter on medical treatment of Parkinson’s disease (PD) concluded that levodopa was the most effective drug for management of this disorder. Since then, a number of new ...
8
Clinical characteristics of impulse control and related disorders in Chinese Parkinson’s disease patients
... dopamine agonists (DA), male gender, young patient, de- pression, smoking, drug abuse, genetic factors, family his- tory of ICRDs and so on [4 – ...Especially, dopamine agonists were thought ...
6
Effects of L Dopa and Dopamine D2 Agonists on Recollection and Familiarity in Idiopathic Nondementing Parkinson’s Disease
... that dopamine depletion contributes to the disease-dependent decline in episodic memory, and therefore, this decline should, at least partially, be remediated by dopaminergic ...D2 dopamine agonist ...
12
NEW INSIGHTS INTO MOLECULAR TARGETS FOR DEPRESSION
... inhibitors, dopamine agonists, targeting GABA) and beyond monoaminergic strategies including corticotropin-releasing factor (CRF)-1 receptor antagonists, Inhibition of glucocorticoid function, substance P ...
7
The potential for selective pharmacological therapies through biased receptor signaling
... different agonists leads to the production of different receptor species with varying preference for signaling proteins, ...different agonists produce different receptor active states; the first proposal of ...
8
Clinical Characteristics and Pathophysiological Features of Restless Legs Syndrome (RLS): Recent Advances and Future Challenges
... the dopamine agonists, ropinirole and pramipexole have been the drugs of choice for patients with moderate to severe RLS, drug emergent problems like augmentation may limit their use for long term ...the ...
14
The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
... non-ergot dopamine agonists; ② MAO-B inhibitors alone, or together with tocopherol; ③ Amantadine; ④ levodopa plus decarboxylase inhibitors (levodopa/benserazide or levodopa/ carbidopa); ⑤ Stalevo ...
12
Investigational agents in the treatment of Parkinson's disease: focus on safinamide
... deficient dopamine, using levodopa, dopamine agonists, and inhibitors of dopamine-metabolizing ...to dopamine agonists improves Unified Parkinson’s Disease Rating Scale motor ...
6